Woodline Partners’s Royalty Pharma RPRX Stock Holding History
Bought
Maintained
Sold
Other funds holding RPRX
Woodline Partners's RPRX Position: Q3 2026 in Review
Woodline Partners increased its Royalty Pharma (RPRX) stake by 19% in Q3 2026, buying an estimated $259K and bringing the position to 27,715 shares worth $1.62M. The position accounts for ﹤0.01% of the portfolio, ranked #909.
Woodline Partners first reported a position in RPRX in Q4 2025 and has held it in 4 quarters since. 707 funds tracked by Wall St. Rank hold RPRX as of Q3 2026.
- Woodline Partners held 27,715 shares of Royalty Pharma worth $1.62M as of Q3 2026.
- Woodline Partners bought 4,385 Royalty Pharma shares in Q3 2026, an estimated $259K.
- Royalty Pharma made up ﹤0.01% of Woodline Partners's portfolio in Q3 2026, its #909 holding.
- Woodline Partners first reported a position in Royalty Pharma in Q4 2025 and has held it in 4 quarters since.
- 707 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2026.
Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.